ObjectiveOur study aims to estimate intra-fraction six-dimensional (6D) tumor motion with rotational correction and the related correlations between motions of different degrees of freedom (DoF), as well as quantify sufficient anisotropic clinical target volume (CTV) to planning target volume (PTV) margins during stereotactic body radiotherapy (SBRT) of liver cancer with fiducial tracking technique.MethodsA cohort of 12 patients who were implanted with 3 or 4 golden markers were included in this study, and 495 orthogonal kilovoltage (kV) pairs of images acquired during the first fraction were used to extract the spacial position of each golden marker. Translational and rotational motions of tumor were calculated based on the marker coordina...
Purpose: We investigated the potentials and limitations of guiding liver stereotactic body radiation...
Contains fulltext : 207179.pdf (Publisher’s version ) (Closed access)PURPOSE: One ...
Purpose: To quantify potential benefits of CTV-to-PTV margin reduction for SBRT of liver tumours, as...
Background: Fiducial markers are the superior method to compensate for interfractional motion in liv...
International audienceAIM:To evaluate the tumor repositioning during gated volumetric modulated arc ...
Purpose: To assess the geometrical accuracy and estimate adequate PTV margins for liver treatments u...
Aim: To investigate tumour motion tracking uncertainties in the CyberKnife Synchrony system with sin...
Purpose: To assess the optimal planning target volume (PTV) margins for stereotactic body radiothera...
Purpose: To investigate in a three-dimensional framework the effectiveness and reproducibility of re...
Background: The purpose of this study is to evaluate the tumor movement and accuracy of patient immo...
Aim: To evaluate liver tumor motion and how well reference measurement predicts motion during treatm...
Spatial accuracy in extracranial radiosurgery is affected by organ motion. Motion tracking systems m...
PURPOSE: To quantify intrafractional motion to determine population-based radiotherapy treatment mar...
Purpose: Positional errors resulting from motion are a principal challenge across all disease sites ...
Purpose: To investigate the potential benefit of multileaf collimator (MLC) tracking guided by kilov...
Purpose: We investigated the potentials and limitations of guiding liver stereotactic body radiation...
Contains fulltext : 207179.pdf (Publisher’s version ) (Closed access)PURPOSE: One ...
Purpose: To quantify potential benefits of CTV-to-PTV margin reduction for SBRT of liver tumours, as...
Background: Fiducial markers are the superior method to compensate for interfractional motion in liv...
International audienceAIM:To evaluate the tumor repositioning during gated volumetric modulated arc ...
Purpose: To assess the geometrical accuracy and estimate adequate PTV margins for liver treatments u...
Aim: To investigate tumour motion tracking uncertainties in the CyberKnife Synchrony system with sin...
Purpose: To assess the optimal planning target volume (PTV) margins for stereotactic body radiothera...
Purpose: To investigate in a three-dimensional framework the effectiveness and reproducibility of re...
Background: The purpose of this study is to evaluate the tumor movement and accuracy of patient immo...
Aim: To evaluate liver tumor motion and how well reference measurement predicts motion during treatm...
Spatial accuracy in extracranial radiosurgery is affected by organ motion. Motion tracking systems m...
PURPOSE: To quantify intrafractional motion to determine population-based radiotherapy treatment mar...
Purpose: Positional errors resulting from motion are a principal challenge across all disease sites ...
Purpose: To investigate the potential benefit of multileaf collimator (MLC) tracking guided by kilov...
Purpose: We investigated the potentials and limitations of guiding liver stereotactic body radiation...
Contains fulltext : 207179.pdf (Publisher’s version ) (Closed access)PURPOSE: One ...
Purpose: To quantify potential benefits of CTV-to-PTV margin reduction for SBRT of liver tumours, as...